Two Sigma Investments
AKBA icon

Two Sigma Investments’s Akebia Therapeutics AKBA Stock Holding History

Two Sigma Investments’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.8M Buy
1,297,801
+1,207,182
+1,332% +$1.66M ﹤0.01% 2834
2025
Q4 		$146K Buy
+90,619
New +$190K ﹤0.01% 3810
2024
Q4 		– Sell
-24,848
Closed -$32.8K – 3176
2024
Q3 		$32.8K Buy
+24,848
New +$33.2K ﹤0.01% 2991
2024
Q1 		– Sell
-185,399
Closed -$230K – 3004
2023
Q4 		$230K Buy
185,399
+157,938
+575% +$161K ﹤0.01% 2780
2023
Q3 		$31.3K Sell
27,461
-188,752
-87% -$242K ﹤0.01% 2847
2023
Q2 		$198K Buy
+216,213
New +$209K ﹤0.01% 2646
2023
Q1 		– Sell
-374,289
Closed -$216K – 2935
2022
Q4 		$216K Sell
374,289
-163,072
-30% -$51.1K ﹤0.01% 2368
2022
Q3 		$170K Buy
537,361
+323,812
+152% +$127K ﹤0.01% 2143
2022
Q2 		$75K Buy
+213,549
New +$89.6K ﹤0.01% 2302
2022
Q1 		– Sell
-97,174
Closed -$220K – 2606
2021
Q4 		$220K Buy
+97,174
New +$265K ﹤0.01% 3853
2021
Q2 		– Sell
-626,577
Closed -$2.12M – 3983
2021
Q1 		$2.12M Buy
626,577
+105,734
+20% +$381K 0.01% 1663
2020
Q4 		$1.46M Buy
+520,843
New +$1.52M ﹤0.01% 1718
2020
Q3 		– Sell
-389,443
Closed -$5.29M – 3041
2020
Q2 		$5.29M Buy
389,443
+369,616
+1,864% +$3.82M 0.03% 621
2020
Q1 		$150K Buy
19,827
+1,777
+10% +$13.8K ﹤0.01% 2744
2019
Q4 		$114K Buy
+18,050
New +$85.8K ﹤0.01% 3513
2019
Q2 		– Sell
-83,546
Closed -$684K – 3285
2019
Q1 		$684K Sell
83,546
-53,309
-39% -$366K ﹤0.01% 2061
2018
Q4 		$757K Buy
136,855
+97,719
+250% +$765K ﹤0.01% 1826
2018
Q3 		$346K Buy
39,136
+16,672
+74% +$149K ﹤0.01% 2680
2018
Q2 		$224K Sell
22,464
-535
-2% -$5.36K ﹤0.01% 3088
2018
Q1 		$219K Buy
+22,999
New +$322K ﹤0.01% 2940
2017
Q4 		– Sell
-154,293
Closed -$3.04M – 3050
2017
Q3 		$3.04M Buy
154,293
+115,208
+295% +$1.77M 0.01% 1073
2017
Q2 		$562K Buy
+39,085
New +$495K ﹤0.01% 2255

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments's AKBA Position: Q1 2026 in Review

Two Sigma Investments increased its Akebia Therapeutics (AKBA) stake by 1,332% in Q1 2026, buying an estimated $1.66M and bringing the position to 1,297,801 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2834.

Two Sigma Investments first reported a position in AKBA in Q2 2017 and has held it in 22 quarters since. The position peaked at $5.29M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Two Sigma Investments held 1,297,801 shares of Akebia Therapeutics worth $1.8M as of Q1 2026.
  • Two Sigma Investments bought 1,207,182 Akebia Therapeutics shares in Q1 2026, an estimated $1.66M.
  • Akebia Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #2834 holding.
  • Two Sigma Investments first reported a position in Akebia Therapeutics in Q2 2017 and has held it in 22 quarters since.
  • Two Sigma Investments's Akebia Therapeutics position peaked at $5.29M in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.